For people with asthma, inflammation in the lungs is a constant, quiet battle. A new kind of inhaled medication, called londamocitinib, just took its first step in human testing. The goal of this early trial was simply to see if it was safe and how it behaved in the body. Researchers gave it to 85 healthy volunteers and 18 people with mild asthma.
In those with asthma, the drug showed a promising sign: it reduced a key marker of lung inflammation, called fractional exhaled nitric oxide (FeNO), by about half. This effect was seen at two different doses and lasted for the 10 days they measured it. The drug was well tolerated after single and multiple doses.
It's crucial to remember what this study is—and isn't. This was a small, early Phase 1 trial designed to check safety and how the drug works in the body, not to prove it helps with symptoms. The reduction in the inflammation marker is an encouraging signal, but we don't yet know if that translates to easier breathing or fewer asthma attacks. The study also didn't include people with more severe asthma, so its effect there is completely unknown.
